ORLANDO, Fla. and CAMBRIDGE, Mass., May 30, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today presented promising data from two clinical trials of IPI-504, the company's heat shock protein 90 (Hsp90) chaperone inhibitor. Preliminary data from the Phase 2 portion of a study in patients with advanced non-small cell lung cancer (NSCLC) and a Phase 1 study of IPI-504 in combination with Taxotere(r) (docetaxel) demonstrate anti-tumor activity, including four partial responses in the Phase 2, and a generally well-tolerated safety profile in both studies. The data were presented during the 2009 American Society for Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida.
